These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25808597)

  • 1. Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable.
    Morimoto M; Bando Y; Nakagawa M; Takechi H; Yoshida T; Honda J; Tadokoro Y; Moriya T; Sasa M; Tangoku A
    Breast Cancer; 2016 Jul; 23(4):577-82. PubMed ID: 25808597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.
    Bae MS; Seo M; Kim KG; Park IA; Moon WK
    Acta Radiol; 2015 Mar; 56(3):269-75. PubMed ID: 24558165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
    Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
    Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.
    Ahmed ST; Ahmed AM; Musa DH; Sulayvani FK; Al-Khyatt M; Pity IS
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):955-959. PubMed ID: 29693354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
    Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
    Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
    Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
    Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells.
    Hida AI; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Moriya T
    Breast Cancer; 2015 Mar; 22(2):129-34. PubMed ID: 23543399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histogram analysis of apparent diffusion coefficient at 3.0t: Correlation with prognostic factors and subtypes of invasive ductal carcinoma.
    Kim EJ; Kim SH; Park GE; Kang BJ; Song BJ; Kim YJ; Lee D; Ahn H; Kim I; Son YH; Grimm R
    J Magn Reson Imaging; 2015 Dec; 42(6):1666-78. PubMed ID: 25919239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance analysis of the anti-Ki67 antibody clone 30-9 for immunohistochemical staining of breast cancer.
    Horii R; Tsuda H; Masuda S; Sugita H; Togashi K; Ohno S; Akiyama F
    Breast Cancer; 2020 Nov; 27(6):1058-1064. PubMed ID: 32440959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis.
    Beatty BG; Bryant R; Wang W; Ashikaga T; Gibson PC; Leiman G; Weaver DL
    Am J Clin Pathol; 2004 Aug; 122(2):246-55. PubMed ID: 15323142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma.
    Faratian D; Munro A; Twelves C; Bartlett JM
    Histopathology; 2009 Jan; 54(2):254-7. PubMed ID: 19207951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High agreement between whole slide imaging and optical microscopy for assessment of HER2 expression in breast cancer: whole slide imaging for the assessment of HER2 expression.
    Nunes C; Rocha R; Buzelin M; Balabram D; Foureaux F; Porto S; Gobbi H
    Pathol Res Pract; 2014 Nov; 210(11):713-8. PubMed ID: 25091257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Availability of fine needle aspirates for the assessment of HER2 gene amplification in invasive breast cancer patients].
    Lee JW; Noh WC; Kim MS; Kim HA; Chang YH; Hong YJ; Hong SI; Lee JK
    Korean J Lab Med; 2008 Oct; 28(5):392-9. PubMed ID: 18971621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination.
    Pegolo E; Machin P; Riosa F; Bassini A; Deroma L; Di Loreto C
    Cancer Cytopathol; 2012 Jun; 120(3):196-205. PubMed ID: 22298467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity?
    Himuro T; Horimoto Y; Arakawa A; Tanabe M; Saito M
    Int J Surg Pathol; 2016 Apr; 24(2):103-7. PubMed ID: 26353854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual assessment of Ki67 using a 5-grade scale (Eye-5) is easy and practical to classify breast cancer subtypes with high reproducibility.
    Hida AI; Bando K; Sugita A; Maeda T; Ueda N; Matsukage S; Nakanishi M; Kito K; Miyazaki T; Ohtsuki Y; Oshiro Y; Inoue H; Kawaguchi H; Yamashita N; Aogi K; Moriya T
    J Clin Pathol; 2015 May; 68(5):356-61. PubMed ID: 25673730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.
    Dieci MV; Barbieri E; Bettelli S; Piacentini F; Omarini C; Ficarra G; Balduzzi S; Dominici M; Conte P; Guarneri V
    J Clin Pathol; 2012 Jun; 65(6):503-6. PubMed ID: 22389512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
    Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K
    BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Human Epidermal Growth Factor Receptor (Her 2/neu) and Proliferative Marker Ki-67: Association with Clinicopathological Parameters in Gallbladder Carcinoma.
    Pujani M; Makker I; Makker A; Jetley S; Goel MM; Jetley S
    Asian Pac J Cancer Prev; 2016; 17(8):3903-9. PubMed ID: 27644637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.